Prospera in Practice: Nursing Strategies for "High-risk" Results

Prospera in Practice: Nursing Strategies for High-Risk Cases

Beyond Biopsy: Cell-free DNA is not just to rule out rejection

PEDAL Study: Prospera™ dd-cfDNA use in post-rejection monitoring

ISHLT 2025 - Enhancing overall dd-cfDNA testing accuracy in heart transplantation using fraction and donor quality score(DQS)

ISHLT 2025- Expanding our Understanding of dd-cfDNA in providing Lung Transplant Personalized Care

Clinical Conundrum: When cDNA & Biopsy Don't Agree

What Nurses Need to Know: Implementing a Prospera™ Surveillance Protocol

Cell-free DNA testing: An alternative option to surveillance biopsy in children

An overview of cell-free DNA technology and its application in pediatric heart transplantation

A Roundtable Conversation on Post-transplant Care

How to Engage Your Kidney Transplant Recipients

Being Proactive with Prospera on Their Transplant Care

In Case you Missed it: Natera's Innovation Pipeline ATC 2024

New Trifecta Study Publication: Prospera dd-cfDNA upheld as a leading indicator for kidney transplant rejection

Satellite Symposium sponsored by Natera

What Nurses Need to Know: New data on implementing the Prospera™ donor-derived cell-free DNA test into your kidney transplant surveillance

Dive into the latest data showcasing the Prospera™ test as a proven leading indicator of rejection - a critical component to any transplant care team's rejection monitoring toolkit.

ISHLT 2023 Lung Symposium

2023 Natera CEoT Symposium

Monitoring Kidney Transplant Recipients: Donor-derived Cell-free DNA (dd-cfDNA) and DSA Can Help Improve Prediction of ABMR